Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H2 2016’, provides an overview of the Kidney Cancer (Renal Cell Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer)

The report reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Kidney Cancer (Renal Cell Cancer) therapeutics and enlists all their major and minor projects

The report assesses Kidney Cancer (Renal Cell Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kidney Cancer (Renal Cell Cancer)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Acceleron Pharma Inc

Adaptimmune Therapeutics Plc

Aduro BioTech Inc

Advanced Cancer Therapeutics

Advenchen Laboratories LLC

Affitech A/S

Alethia Biotherapeutics Inc

Altor BioScience Corp

Ambrx Inc

Amgen Inc

Ampio Pharmaceuticals Inc

Apac Biotech Pvt Ltd

Apcure SAS

APEIRON Biologics AG

Aphios Corp

Aptevo Therapeutics Inc

Aravive Biologics Inc

arGEN-X BV

Argos Therapeutics Inc

ARMO Biosciences Inc

ArQule Inc

Arrowhead Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

ATLAB Pharma SAS

Bayer AG

BeiGene Ltd

Berg LLC

Bio-Cancer Treatment International Ltd

Biocad

Bionomics Ltd

Bionovis SA

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

CASI Pharmaceuticals Inc

Celgene Corp

Cellceutix Corp

Celldex Therapeutics Inc

Cellular Biomedicine Group Inc

Chipscreen Biosciences Ltd

Cleave Biosciences Inc

COARE Biotechnology Inc

Coherus BioSciences Inc

Corcept Therapeutics Inc

Corvus Pharmaceuticals Inc

Cytune Pharma SAS

Daiichi Sankyo Company Ltd

Dr. Reddy's Laboratories Ltd

Ecrins Therapeutics SAS

EirGenix Inc

Eisai Co Ltd

Eli Lilly and Company

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Five Prime Therapeutics Inc

Gene Techno Science Co Ltd

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

Glycotope GmbH

HEC Pharm Co Ltd

Hemispherx Biopharma Inc

Horizon Pharma Plc

Hutchison MediPharma Ltd

Immatics Biotechnologies GmbH

Immune Design Corp

Immunicum AB

ImmunoFrontier Inc

ImmunoGen Inc

Immunomedics Inc

Incuron LLC

Incyte Corp

Innate Immunotherapeutics Ltd

Inspyr Therapeutics Inc

Intech Biopharm Ltd

Johnson & Johnson

KAHR medical Ltd

Karyopharm Therapeutics Inc

KineMed Inc

Komipharm International Co Ltd

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Mabion SA

MacroGenics Inc

MaxiVAX SA

MediaPharma srl

MedImmune LLC

Medivation Inc

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Molecular Partners AG

Moleculin Biotech Inc

Monopar Therapeutics LLC

Mycenax Biotech Inc

NanoSmart Pharmaceuticals Inc

Nektar Therapeutics

NewLink Genetics Corp

Novartis AG

NovaTarg Therapeutics Inc

Omeros Corp

OncBioMune Pharmaceuticals Inc

Oncobiologics Inc

Oncolys BioPharma Inc

OncoMax

OncoTherapy Science Inc

Ono Pharmaceutical Co Ltd

Peloton Therapeutics Inc

Pfizer Inc

Pharma Mar SA

Pharmacyclics Inc

Pharmicell Co Ltd

Pivotal BioSciences Inc

Prima BioMed Ltd

PsiOxus Therapeutics Ltd

Recombio SL

Rexahn Pharmaceuticals Inc

Richter Gedeon Nyrt

Sanofi

Selvita SA

Sevion Therapeutics Inc

Shanghai Henlius Biotech Co Ltd

Sillajen Biotherapeutics

Sorrento Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Syndax Pharmaceuticals Inc

Synthon Holdings BV

Taiwan Liposome Company Ltd

Takeda Pharmaceutical Company Ltd

Tara Immuno-Oncology Therapeutics LLC

Taris Biomedical LLC

TC BioPharm Ltd

Teva Pharmaceutical Industries Ltd

Theravectys SA

Tocagen Inc

TRACON Pharmaceuticals Inc

TVAX Biomedical Inc

Tyrogenex Inc

UroGen Pharmaceuticals Ltd

Valeant Pharmaceuticals International Inc

Vascular Biogenics Ltd

Vault Pharma Inc

Vaxeal Holding SA

Vyriad Inc

X4 Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Kidney Cancer (Renal Cell Cancer) Overview 9

Therapeutics Development 10

Kidney Cancer (Renal Cell Cancer) - Therapeutics under Development by Companies 12

Kidney Cancer (Renal Cell Cancer) - Therapeutics under Investigation by Universities/Institutes 23

Kidney Cancer (Renal Cell Cancer) - Pipeline Products Glance 25

Kidney Cancer (Renal Cell Cancer) - Products under Development by Companies 29

Kidney Cancer (Renal Cell Cancer) - Products under Investigation by Universities/Institutes 49

Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development 51

Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment 201

Drug Profiles 235

Kidney Cancer (Renal Cell Cancer) - Dormant Projects 1040

Kidney Cancer (Renal Cell Cancer) - Discontinued Products 1064

Kidney Cancer (Renal Cell Cancer) - Product Development Milestones 1069

Appendix 1083

List of Tables

List of Tables

Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2016 39

Number of Products under Development for Kidney Cancer (Renal Cell Cancer) – Comparative Analysis, H2 2016 40

Number of Products under Development by Companies, H2 2016 41

Number of Products under Development by Companies, H2 2016 (Contd..1) 42

Number of Products under Development by Companies, H2 2016 (Contd..2) 43

Number of Products under Development by Companies, H2 2016 (Contd..3) 44

Number of Products under Development by Companies, H2 2016 (Contd..4) 45

Number of Products under Development by Companies, H2 2016 (Contd..5) 46

Number of Products under Development by Companies, H2 2016 (Contd..6) 47

Number of Products under Development by Companies, H2 2016 (Contd..7) 48

Number of Products under Development by Companies, H2 2016 (Contd..8) 49

Number of Products under Development by Companies, H2 2016 (Contd..9) 50

Number of Products under Development by Companies, H2 2016 (Contd..10) 51

Number of Products under Investigation by Universities/Institutes, H2 2016 53

Comparative Analysis by Late Stage Development, H2 2016 54

Comparative Analysis by Clinical Stage Development, H2 2016 55

Comparative Analysis by Early Stage Development, H2 2016 56

Comparative Analysis by Unknown Stage Development, H2 2016 57

Products under Development by Companies, H2 2016 58

Products under Development by Companies, H2 2016 (Contd..1) 59

Products under Development by Companies, H2 2016 (Contd..2) 60

Products under Development by Companies, H2 2016 (Contd..3) 61

Products under Development by Companies, H2 2016 (Contd..4) 62

Products under Development by Companies, H2 2016 (Contd..5) 63

Products under Development by Companies, H2 2016 (Contd..6) 64

Products under Development by Companies, H2 2016 (Contd..7) 65

Products under Development by Companies, H2 2016 (Contd..8) 66

Products under Development by Companies, H2 2016 (Contd..9) 67

Products under Development by Companies, H2 2016 (Contd..10) 68

Products under Development by Companies, H2 2016 (Contd..11) 69

Products under Development by Companies, H2 2016 (Contd..12) 70

Products under Development by Companies, H2 2016 (Contd..13) 71

Products under Development by Companies, H2 2016 (Contd..14) 72

Products under Development by Companies, H2 2016 (Contd..15) 73

Products under Development by Companies, H2 2016 (Contd..16) 74

Products under Development by Companies, H2 2016 (Contd..17) 75

Products under Development by Companies, H2 2016 (Contd..18) 76

Products under Development by Companies, H2 2016 (Contd..19) 77

Products under Investigation by Universities/Institutes, H2 2016 78

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 79

Kidney Cancer (Renal Cell Cancer) – Pipeline by 4SC AG, H2 2016 80

Kidney Cancer (Renal Cell Cancer) – Pipeline by AbbVie Inc, H2 2016 81

Kidney Cancer (Renal Cell Cancer) – Pipeline by Acceleron Pharma Inc, H2 2016 82

Kidney Cancer (Renal Cell Cancer) – Pipeline by Adaptimmune Therapeutics Plc, H2 2016 83

Kidney Cancer (Renal Cell Cancer) – Pipeline by Aduro BioTech Inc, H2 2016 84

Kidney Cancer (Renal Cell Cancer) – Pipeline by Advanced Cancer Therapeutics, H2 2016 85

Kidney Cancer (Renal Cell Cancer) – Pipeline by Advenchen Laboratories LLC, H2 2016 86

Kidney Cancer (Renal Cell Cancer) – Pipeline by Affitech A/S, H2 2016 87

Kidney Cancer (Renal Cell Cancer) – Pipeline by Alethia Biotherapeutics Inc, H2 2016 88

Kidney Cancer (Renal Cell Cancer) – Pipeline by Altor BioScience Corp, H2 2016 89

Kidney Cancer (Renal Cell Cancer) – Pipeline by Ambrx Inc, H2 2016 90

Kidney Cancer (Renal Cell Cancer) – Pipeline by Amgen Inc, H2 2016 91

Kidney Cancer (Renal Cell Cancer) – Pipeline by Ampio Pharmaceuticals Inc, H2 2016 92

Kidney Cancer (Renal Cell Cancer) – Pipeline by Apac Biotech Pvt Ltd, H2 2016 93

Kidney Cancer (Renal Cell Cancer) – Pipeline by Apcure SAS, H2 2016 94

Kidney Cancer (Renal Cell Cancer) – Pipeline by APEIRON Biologics AG, H2 2016 95

Kidney Cancer (Renal Cell Cancer) – Pipeline by Aphios Corp, H2 2016 96

Kidney Cancer (Renal Cell Cancer) – Pipeline by Aptevo Therapeutics Inc, H2 2016 97

Kidney Cancer (Renal Cell Cancer) – Pipeline by Aravive Biologics Inc, H2 2016 98

Kidney Cancer (Renal Cell Cancer) – Pipeline by arGEN-X BV, H2 2016 99

Kidney Cancer (Renal Cell Cancer) – Pipeline by Argos Therapeutics Inc, H2 2016 100

Kidney Cancer (Renal Cell Cancer) – Pipeline by ARMO Biosciences Inc, H2 2016 101

Kidney Cancer (Renal Cell Cancer) – Pipeline by ArQule Inc, H2 2016 102

Kidney Cancer (Renal Cell Cancer) – Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 103

Kidney Cancer (Renal Cell Cancer) – Pipeline by Astellas Pharma Inc, H2 2016 104

Kidney Cancer (Renal Cell Cancer) – Pipeline by AstraZeneca Plc, H2 2016 105

Kidney Cancer (Renal Cell Cancer) – Pipeline by ATLAB Pharma SAS, H2 2016 106

Kidney Cancer (Renal Cell Cancer) – Pipeline by Bayer AG, H2 2016 107

Kidney Cancer (Renal Cell Cancer) – Pipeline by BeiGene Ltd, H2 2016 108

Kidney Cancer (Renal Cell Cancer) – Pipeline by Berg LLC, H2 2016 109

Kidney Cancer (Renal Cell Cancer) – Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 110

Kidney Cancer (Renal Cell Cancer) – Pipeline by Biocad, H2 2016 111

Kidney Cancer (Renal Cell Cancer) – Pipeline by Bionomics Ltd, H2 2016 112

Kidney Cancer (Renal Cell Cancer) – Pipeline by Bionovis SA, H2 2016 113

Kidney Cancer (Renal Cell Cancer) – Pipeline by Boehringer Ingelheim GmbH, H2 2016 114

Kidney Cancer (Renal Cell Cancer) – Pipeline by Boston Biomedical Inc, H2 2016 115

Kidney Cancer (Renal Cell Cancer) – Pipeline by Bristol-Myers Squibb Company, H2 2016 116

Kidney Cancer (Renal Cell Cancer) – Pipeline by Calithera Biosciences Inc, H2 2016 117

Kidney Cancer (Renal Cell Cancer) – Pipeline by CASI Pharmaceuticals Inc, H2 2016 118

Kidney Cancer (Renal Cell Cancer) – Pipeline by Celgene Corp, H2 2016 119

Kidney Cancer (Renal Cell Cancer) – Pipeline by Cellceutix Corp, H2 2016 120

Kidney Cancer (Renal Cell Cancer) – Pipeline by Celldex Therapeutics Inc, H2 2016 121

Kidney Cancer (Renal Cell Cancer) – Pipeline by Cellular Biomedicine Group Inc, H2 2016 122

Kidney Cancer (Renal Cell Cancer) – Pipeline by Chipscreen Biosciences Ltd, H2 2016 123

Kidney Cancer (Renal Cell Cancer) – Pipeline by Cleave Biosciences Inc, H2 2016 124

Kidney Cancer (Renal Cell Cancer) – Pipeline by COARE Biotechnology Inc, H2 2016 125

Kidney Cancer (Renal Cell Cancer) – Pipeline by Coherus BioSciences Inc, H2 2016 126

Kidney Cancer (Renal Cell Cancer) – Pipeline by Corcept Therapeutics Inc, H2 2016 127

Kidney Cancer (Renal Cell Cancer) – Pipeline by Corvus Pharmaceuticals Inc, H2 2016 128

Kidney Cancer (Renal Cell Cancer) – Pipeline by Cytune Pharma SAS, H2 2016 129

Kidney Cancer (Renal Cell Cancer) – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 130

Kidney Cancer (Renal Cell Cancer) – Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 131

Kidney Cancer (Renal Cell Cancer) – Pipeline by Ecrins Therapeutics SAS, H2 2016 132

Kidney Cancer (Renal Cell Cancer) – Pipeline by EirGenix Inc, H2 2016 133

Kidney Cancer (Renal Cell Cancer) – Pipeline by Eisai Co Ltd, H2 2016 134

Kidney Cancer (Renal Cell Cancer) – Pipeline by Eli Lilly and Company, H2 2016 135

Kidney Cancer (Renal Cell Cancer) – Pipeline by Esperance Pharmaceuticals Inc, H2 2016 136

Kidney Cancer (Renal Cell Cancer) – Pipeline by Exelixis Inc, H2 2016 137

Kidney Cancer (Renal Cell Cancer) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 138

Kidney Cancer (Renal Cell Cancer) – Pipeline by Five Prime Therapeutics Inc, H2 2016 139

Kidney Cancer (Renal Cell Cancer) – Pipeline by Gene Techno Science Co Ltd, H2 2016 140

Kidney Cancer (Renal Cell Cancer) – Pipeline by Genor BioPharma Co Ltd, H2 2016 141

Kidney Cancer (Renal Cell Cancer) – Pipeline by GlaxoSmithKline Plc, H2 2016 142

Kidney Cancer (Renal Cell Cancer) – Pipeline by Glycotope GmbH, H2 2016 143

Kidney Cancer (Renal Cell Cancer) – Pipeline by HEC Pharm Co Ltd, H2 2016 144

Kidney Cancer (Renal Cell Cancer) – Pipeline by Hemispherx Biopharma Inc, H2 2016 145

Kidney Cancer (Renal Cell Cancer) – Pipeline by Horizon Pharma Plc, H2 2016 146

Kidney Cancer (Renal Cell Cancer) – Pipeline by Hutchison MediPharma Ltd, H2 2016 147

Kidney Cancer (Renal Cell Cancer) – Pipeline by Immatics Biotechnologies GmbH, H2 2016 148

Kidney Cancer (Renal Cell Cancer) – Pipeline by Immune Design Corp, H2 2016 149

Kidney Cancer (Renal Cell Cancer) – Pipeline by Immunicum AB, H2 2016 150

Kidney Cancer (Renal Cell Cancer) – Pipeline by ImmunoFrontier Inc, H2 2016 151

Kidney Cancer (Renal Cell Cancer) – Pipeline by ImmunoGen Inc, H2 2016 152

Kidney Cancer (Renal Cell Cancer) – Pipeline by Immunomedics Inc, H2 2016 153

Kidney Cancer (Renal Cell Cancer) – Pipeline by Incuron LLC, H2 2016 154

Kidney Cancer (Renal Cell Cancer) – Pipeline by Incyte Corp, H2 2016 155

Kidney Cancer (Renal Cell Cancer) – Pipeline by Innate Immunotherapeutics Ltd, H2 2016 156

Kidney Cancer (Renal Cell Cancer) – Pipeline by Inspyr Therapeutics Inc, H2 2016 157

Kidney Cancer (Renal Cell Cancer) – Pipeline by Intech Biopharm Ltd, H2 2016 158

Kidney Cancer (Renal Cell Cancer) – Pipeline by Johnson & Johnson, H2 2016 159

Kidney Cancer (Renal Cell Cancer) – Pipeline by KAHR medical Ltd, H2 2016 160

Kidney Cancer (Renal Cell Cancer) – Pipeline by Karyopharm Therapeutics Inc, H2 2016 161

Kidney Cancer (Renal Cell Cancer) – Pipeline by KineMed Inc, H2 2016 162

Kidney Cancer (Renal Cell Cancer) – Pipeline by Komipharm International Co Ltd, H2 2016 163

Kidney Cancer (Renal Cell Cancer) – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 164

Kidney Cancer (Renal Cell Cancer) – Pipeline by Lead Discovery Center GmbH, H2 2016 165

Kidney Cancer (Renal Cell Cancer) – Pipeline by Mabion SA, H2 2016 166

Kidney Cancer (Renal Cell Cancer) – Pipeline by MacroGenics Inc, H2 2016 167

Kidney Cancer (Renal Cell Cancer) – Pipeline by MaxiVAX SA, H2 2016 168

Kidney Cancer (Renal Cell Cancer) – Pipeline by MediaPharma srl, H2 2016 169

Kidney Cancer (Renal Cell Cancer) – Pipeline by MedImmune LLC, H2 2016 170

Kidney Cancer (Renal Cell Cancer) – Pipeline by Medivation Inc, H2 2016 171

Kidney Cancer (Renal Cell Cancer) – Pipeline by Merck & Co Inc, H2 2016 172

Kidney Cancer (Renal Cell Cancer) – Pipeline by Merck KGaA, H2 2016 173

Kidney Cancer (Renal Cell Cancer) – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 174

Kidney Cancer (Renal Cell Cancer) – Pipeline by Mirati Therapeutics Inc, H2 2016 175

Kidney Cancer (Renal Cell Cancer) – Pipeline by Molecular Partners AG, H2 2016 176

Kidney Cancer (Renal Cell Cancer) – Pipeline by Moleculin Biotech Inc, H2 2016 177

Kidney Cancer (Renal Cell Cancer) – Pipeline by Monopar Therapeutics LLC, H2 2016 178

Kidney Cancer (Renal Cell Cancer) – Pipeline by Mycenax Biotech Inc, H2 2016 179

Kidney Cancer (Renal Cell Cancer) – Pipeline by NanoSmart Pharmaceuticals Inc, H2 2016 180

Kidney Cancer (Renal Cell Cancer) – Pipeline by Nektar Therapeutics, H2 2016 181

Kidney Cancer (Renal Cell Cancer) – Pipeline by NewLink Genetics Corp, H2 2016 182

Kidney Cancer (Renal Cell Cancer) – Pipeline by Novartis AG, H2 2016 183

Kidney Cancer (Renal Cell Cancer) – Pipeline by NovaTarg Therapeutics Inc, H2 2016 184

Kidney Cancer (Renal Cell Cancer) – Pipeline by Omeros Corp, H2 2016 185

Kidney Cancer (Renal Cell Cancer) – Pipeline by OncBioMune Pharmaceuticals Inc, H2 2016 186

Kidney Cancer (Renal Cell Cancer) – Pipeline by Oncobiologics Inc, H2 2016 187

Kidney Cancer (Renal Cell Cancer) – Pipeline by Oncolys BioPharma Inc, H2 2016 188

Kidney Cancer (Renal Cell Cancer) – Pipeline by OncoMax, H2 2016 189

Kidney Cancer (Renal Cell Cancer) – Pipeline by OncoTherapy Science Inc, H2 2016 190

Kidney Cancer (Renal Cell Cancer) – Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 191

Kidney Cancer (Renal Cell Cancer) – Pipeline by Peloton Therapeutics Inc, H2 2016 192

Kidney Cancer (Renal Cell Cancer) – Pipeline by Pfizer Inc, H2 2016 193

Kidney Cancer (Renal Cell Cancer) – Pipeline by Pharma Mar SA, H2 2016 194

Kidney Cancer (Renal Cell Cancer) – Pipeline by Pharmacyclics Inc, H2 2016 195

Kidney Cancer (Renal Cell Cancer) – Pipeline by Pharmicell Co Ltd, H2 2016 196

Kidney Cancer (Renal Cell Cancer) – Pipeline by Pivotal BioSciences Inc, H2 2016 197

Kidney Cancer (Renal Cell Cancer) – Pipeline by Prima BioMed Ltd, H2 2016 198

Kidney Cancer (Renal Cell Cancer) – Pipeline by PsiOxus Therapeutics Ltd, H2 2016 199

Kidney Cancer (Renal Cell Cancer) – Pipeline by Recombio SL, H2 2016 200

Kidney Cancer (Renal Cell Cancer) – Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 201

Kidney Cancer (Renal Cell Cancer) – Pipeline by Richter Gedeon Nyrt, H2 2016 202

Kidney Cancer (Renal Cell Cancer) – Pipeline by Sanofi, H2 2016 203

Kidney Cancer (Renal Cell Cancer) – Pipeline by Selvita SA, H2 2016 204

Kidney Cancer (Renal Cell Cancer) – Pipeline by Sevion Therapeutics Inc, H2 2016 205

Kidney Cancer (Renal Cell Cancer) – Pipeline by Shanghai Henlius Biotech Co Ltd, H2 2016 206

Kidney Cancer (Renal Cell Cancer) – Pipeline by Sillajen Biotherapeutics, H2 2016 207

Kidney Cancer (Renal Cell Cancer) – Pipeline by Sorrento Therapeutics Inc, H2 2016 208

Kidney Cancer (Renal Cell Cancer) – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 209

Kidney Cancer (Renal Cell Cancer) – Pipeline by Syndax Pharmaceuticals Inc, H2 2016 210

Kidney Cancer (Renal Cell Cancer) – Pipeline by Synthon Holdings BV, H2 2016 211

Kidney Cancer (Renal Cell Cancer) – Pipeline by Taiwan Liposome Company Ltd, H2 2016 212

Kidney Cancer (Renal Cell Cancer) – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 213

Kidney Cancer (Renal Cell Cancer) – Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 214

Kidney Cancer (Renal Cell Cancer) – Pipeline by Taris Biomedical LLC, H2 2016 215

Kidney Cancer (Renal Cell Cancer) – Pipeline by TC BioPharm Ltd, H2 2016 216

Kidney Cancer (Renal Cell Cancer) – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 217

Kidney Cancer (Renal Cell Cancer) – Pipeline by Theravectys SA, H2 2016 218

Kidney Cancer (Renal Cell Cancer) – Pipeline by Tocagen Inc, H2 2016 219

Kidney Cancer (Renal Cell Cancer) – Pipeline by TRACON Pharmaceuticals Inc, H2 2016 220

Kidney Cancer (Renal Cell Cancer) – Pipeline by TVAX Biomedical Inc, H2 2016 221

Kidney Cancer (Renal Cell Cancer) – Pipeline by Tyrogenex Inc, H2 2016 222

Kidney Cancer (Renal Cell Cancer) – Pipeline by UroGen Pharmaceuticals Ltd, H2 2016 223

Kidney Cancer (Renal Cell Cancer) – Pipeline by Valeant Pharmaceuticals International Inc, H2 2016 224

Kidney Cancer (Renal Cell Cancer) – Pipeline by Vascular Biogenics Ltd, H2 2016 225

Kidney Cancer (Renal Cell Cancer) – Pipeline by Vault Pharma Inc, H2 2016 226

Kidney Cancer (Renal Cell Cancer) – Pipeline by Vaxeal Holding SA, H2 2016 227

Kidney Cancer (Renal Cell Cancer) – Pipeline by Vyriad Inc, H2 2016 228

Kidney Cancer (Renal Cell Cancer) – Pipeline by X4 Pharmaceuticals Inc, H2 2016 229

Assessment by Monotherapy Products, H2 2016 230

Assessment by Combination Products, H2 2016 231

Number of Products by Stage and Target, H2 2016 233

Number of Products by Stage and Mechanism of Action, H2 2016 247

Number of Products by Stage and Route of Administration, H2 2016 262

Number of Products by Stage and Molecule Type, H2 2016 264

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, H2 2016 1070

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..1), H2 2016 1071

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..2), H2 2016 1072

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..3), H2 2016 1073

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..4), H2 2016 1074

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..5), H2 2016 1075

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..6), H2 2016 1076

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..7), H2 2016 1077

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..8), H2 2016 1078

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..9), H2 2016 1079

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..10), H2 2016 1080

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..11), H2 2016 1081

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..12), H2 2016 1082

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..13), H2 2016 1083

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..14), H2 2016 1084

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..15), H2 2016 1085

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..16), H2 2016 1086

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..17), H2 2016 1087

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..18), H2 2016 1088

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..19), H2 2016 1089

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..20), H2 2016 1090

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..21), H2 2016 1091

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..22), H2 2016 1092

Kidney Cancer (Renal Cell Cancer) – Dormant Projects (Contd..23), H2 2016 1093

Kidney Cancer (Renal Cell Cancer) – Discontinued Products, H2 2016 1094

Kidney Cancer (Renal Cell Cancer) – Discontinued Products (Contd..1), H2 2016 1095

Kidney Cancer (Renal Cell Cancer) – Discontinued Products (Contd..2), H2 2016 1096

Kidney Cancer (Renal Cell Cancer) – Discontinued Products (Contd..3), H2 2016 1097

Kidney Cancer (Renal Cell Cancer) – Discontinued Products (Contd..4), H2 2016 1098

List of Figures

List of Figures

Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2016 39

Number of Products under Development for Kidney Cancer (Renal Cell Cancer) – Comparative Analysis, H2 2016 40

Number of Products under Development by Companies, H2 2016 41

Number of Products under Investigation by Universities/Institutes, H2 2016 52

Comparative Analysis by Late Stage Development, H2 2016 54

Comparative Analysis by Clinical Stage Development, H2 2016 55

Comparative Analysis by Early Stage Products, H2 2016 56

Assessment by Monotherapy Products, H2 2016 230

Assessment by Combination Products, H2 2016 231

Number of Products by Top 10 Targets, H2 2016 232

Number of Products by Stage and Top 10 Targets, H2 2016 232

Number of Products by Top 10 Mechanism of Actions, H2 2016 246

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 246

Number of Products by Top 10 Routes of Administration, H2 2016 261

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 261

Number of Products by Top 10 Molecule Types, H2 2016 263

Number of Products by Stage and Top 10 Molecule Types, H2 2016 263

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports